卡培他滨与替吉奥对HER-2阳性乳腺癌抑癌基因表达及血清CA125、CA199、CEA水平的影响  

Effect of capecitabine versus tegafur-gimeracil-oteracil on tumor suppressor genes and serum CA125/199 and CEA levels in HER-2 positive breast cancer

作　　者：梁劲文 白剑[1] 苏少琴 何淑媚[1] 梁凤兴 LIANG Jing-wen;BAI Jian;SU Shao-qing;HE Shu-mei;LIANG Feng-xing(Nanhai Maternal and Child Health Hospital,Foshan 528200,China)

机构地区：[1]佛山市南海区妇幼保健院,广东佛山528200

出　　处：《广东医科大学学报》2021年第4期424-428,共5页Journal of Guangdong Medical University

摘　　要：目的比较卡培他滨与替吉奥治疗对人表皮生长因子受体-2(HER-2)阳性乳腺癌的抑癌基因表达及血清糖类抗原199(CA199)、CA125、癌胚抗原(CEA)水平的影响。方法86例HER-2阳性乳腺癌患者分别采用替吉奥(对照组)或卡培他滨(观察组)化疗,比较两组总有效率、生存率、肿瘤标志物、抑癌基因表达及毒性反应。结果治疗2、4周期后,观察组疗效与对照组差异无统计学意义(P>0.05)。观察组Ⅰ~Ⅱ级毒性反应及CA199、CA125、CEA水平明显低于对照组(P<0.01或0.05),生存率及Caspase-3、FasL、ARID1A、Bax、PTEN mRNA表达高于对照组(P<0.01或0.05)。结论卡培他滨化疗可提高HER-2阳性乳腺癌患者生存率,改善血清肿瘤标志物及抑癌基因表达情况。Objective To compare the effect of capecitabine and tegafur-gimeracil-oteracil(TGO)on tumor suppressor genes and serum carbohydrate antigen(CA)125/199 and carcinoembryonic antigen(CEA)levels in human epidermal growth factor receptor 2(HER-2)positive breast cancer.Methods Eighty-six patients with HER-2 positive breast cancer were treated with TGO(control group)or capecitabine(observation group)chemotherapy.Overall effective rate,survival rate,tumor markers,tumor suppressor genes and toxicity were compared between 2 groups.Results The overall effective rate was comparable between 2 groups(P>0.05)after 2 and chemotherapy cycles.Compared with control group,gradeⅠ-Ⅱtoxic reactions and serum CA125/199 and CEA levels were lower(P<0.01 or 0.05),while survival rate and expression of Caspase-3,FasL,ARID1A,Bax,and PTEN mRNA were higher(P<0.01 or 0.05)in observation group.Conclusion Capecitabine chemotherapy can improve survival rate and expression of serum tumor markers and tumor suppressor genes in patients with HER-2 positive breast cancer.

关 键 词：乳腺癌 卡培他滨 替吉奥 人表皮生长因子受体-2 

分 类 号：R711[医药卫生—妇产科学]